Dicerna Pharmaceuticals Inc (DRNA) Expected to Announce Quarterly Sales of $1.79 Million


Analysts expect that Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) will post $1.79 million in sales for the current fiscal quarter, Zacks Investment Research reports. Three analysts have provided estimates for Dicerna Pharmaceuticals’ earnings, with the lowest sales estimate coming in at $1.70 million and the highest estimate coming in at $1.92 million. Dicerna Pharmaceuticals posted sales of $250,000.00 in the same quarter last year, which suggests a positive year-over-year growth rate of 616%. The business is scheduled to issue its next earnings report on Thursday, August 9th.


On average, analysts expect that Dicerna Pharmaceuticals will report full-year sales of $5.91 million for the current financial year, with estimates ranging from $2.00 million to $7.97 million. For the next financial year, analysts forecast that the company will report sales of $12.17 million per share, with estimates ranging from $3.10 million to $26.67 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research firms that follow Dicerna Pharmaceuticals.

Get Dicerna Pharmaceuticals alerts:


Dicerna Pharmaceuticals (NASDAQ:DRNA) last announced its earnings results on Monday, May 14th. The biopharmaceutical company reported ($0.30) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.87) by $0.57. The company had revenue of $1.55 million during the quarter, compared to the consensus estimate of $1.75 million. Dicerna Pharmaceuticals had a negative net margin of 1,665.11% and a negative return on equity of 123.72%.

Several equities research analysts have recently commented on DRNA shares. BidaskClub downgraded shares of Dicerna Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday. Cowen reiterated a “buy” rating on shares of Dicerna Pharmaceuticals in a research note on Tuesday, April 24th. B. Riley started coverage on shares of Dicerna Pharmaceuticals in a research note on Wednesday, March 28th. They set a “neutral” rating and a $10.00 price objective for the company. ValuEngine upgraded shares of Dicerna Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, April 12th. Finally, Chardan Capital started coverage on shares of Dicerna Pharmaceuticals in a research note on Friday, March 9th. They set a “neutral” rating for the company. One research analyst has rated the stock with a sell rating, four have given a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Dicerna Pharmaceuticals currently has a consensus rating of “Buy” and a consensus target price of $12.88.


In related news, insider James B. Weissman sold 10,000 shares of the firm’s stock in a transaction on Wednesday, May 9th. The shares were sold at an average price of $15.00, for a total transaction of $150,000.00. Following the completion of the transaction, the insider now owns 19,800 shares of the company’s stock, valued at $297,000. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider James B. Weissman sold 8,965 shares of the firm’s stock in a transaction on Friday, April 20th. The stock was sold at an average price of $13.00, for a total transaction of $116,545.00. Following the transaction, the insider now directly owns 9,800 shares of the company’s stock, valued at approximately $127,400. The disclosure for this sale can be found here. Insiders have sold 20,000 shares of company stock valued at $280,000 over the last quarter. Insiders own 19.85% of the company’s stock.


Institutional investors have recently modified their holdings of the stock. Cubist Systematic Strategies LLC purchased a new position in shares of Dicerna Pharmaceuticals during the first quarter worth $102,000. Quantitative Systematic Strategies LLC purchased a new position in shares of Dicerna Pharmaceuticals during the first quarter worth $113,000. Caxton Corp purchased a new position in shares of Dicerna Pharmaceuticals during the first quarter worth $125,000. Jane Street Group LLC purchased a new position in shares of Dicerna Pharmaceuticals during the first quarter worth $136,000. Finally, Verition Fund Management LLC purchased a new position in shares of Dicerna Pharmaceuticals during the first quarter worth $141,000. 77.28% of the stock is owned by hedge funds and other institutional investors.


DRNA traded down $0.08 during trading on Friday, hitting $12.50. The stock had a trading volume of 667,152 shares, compared to its average volume of 510,417. The company has a market cap of $688.27 million, a price-to-earnings ratio of -3.42 and a beta of 2.34. Dicerna Pharmaceuticals has a twelve month low of $2.69 and a twelve month high of $15.80.

About Dicerna Pharmaceuticals

Dicerna Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery and development of pharmaceuticals for the treatment of rare, viral infectious, chronic liver, and cardiovascular diseases. Its development programs include DCR-PHXC for the treatment of primary hyperoxaluria; DCR-HBVS for the treatment of chronic hepatitis B virus infection; and DCR-PCSK9 to treat hypercholesterolemia.

Get a free copy of the Zacks research report on Dicerna Pharmaceuticals (DRNA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Dicerna Pharmaceuticals (NASDAQ:DRNA)

Leave a Reply

Your email address will not be published. Required fields are marked *